Literature DB >> 31342537

Systematic review with meta-analysis: risk factors for thiopurine-induced leukopenia in IBD.

Sara van Gennep1, Kadère Konté1, Berrie Meijer2, Martijn W Heymans3, Geert R D'Haens1, Mark Löwenberg1, Nanne K H de Boer2.   

Abstract

BACKGROUND: Thiopurine-induced leukopenia, a frequently observed and potentially life-threatening adverse event, complicates the clinical management of IBD patients. AIM: To assess risk factors for thiopurine-induced leukopenia in IBD.
METHODS: MEDLINE, EMBASE, BIOSIS and Cochrane library were searched for studies reporting at least one risk factor for thiopurine-induced leukopenia. Pooled odds ratio (OR) was calculated for each potential risk factor using a random effects model. Studies that were not eligible for meta-analysis were described qualitatively.
RESULTS: Seventy articles were included, 34 (11 229 patients) were included in meta-analyses. A significantly higher thiopurine-induced leukopenia risk was found for TPMT (OR 3.9, 95% [CI] 2.5-6.1) and for NUDT15 R139C (OR 6.9, 95% CI 5.2-9.1), G52A (OR 3.2, 95% CI 1.3-7.9) and 36_37ins/delGGAGTC variant carriers (OR 5.6, 95% CI 2.8-11.4). A potential association between high 6-thioguanine nucleotides (6-TGN) or 6-methylmercaptopurine (6-MMP) levels and leukopenia was observed, since most studies reported higher metabolite levels in leukopenic patients (6-TGN: 204-308 (Lennard method) and 397 (Dervieux method), 6-MMP: 4020-10 450 pmol/8 x 108 RBC) compared to controls (6-TGN: 170-212 (Lennard method) and 269 (Dervieux method), 6-MMP: 1025-4550 pmol/8 x 108 RBC).
CONCLUSIONS: TPMT and NUDT15 variants predict thiopurine-induced leukopenia. High 6-TGN and 6-MMP levels might induce leukopenia, although exact cut-off values remain unclear. Potential preventive measures to reduce the risk of thiopurine-induced leukopenia include pre-treatment TPMT and NUDT15 genotyping. Routine thiopurine metabolite measurement might be efficient, yet cut-off levels must be validated in advance.
© 2019 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31342537     DOI: 10.1111/apt.15403

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  9 in total

1.  NUDT15 genotyping in Caucasian patients can help to optimise thiopurine treatment in patients with inflammatory bowel disease.

Authors:  Marieke J H Coenen
Journal:  Transl Gastroenterol Hepatol       Date:  2019-12-12

Review 2.  Is Monitoring of the Intracellular Active Metabolite Levels of Nucleobase and Nucleoside Analogs Ready for Precision Medicine Applications?

Authors:  Shenjia Huang; Yicong Bian; Chenrong Huang; Liyan Miao
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2022-08-01       Impact factor: 2.569

Review 3.  Low-Dose Azathioprine in Combination with Allopurinol: The Past, Present and Future of This Useful Duo.

Authors:  Alexander Keith Turbayne; Miles Patrick Sparrow
Journal:  Dig Dis Sci       Date:  2022-10-15       Impact factor: 3.487

4.  Thiopurine S-methyltransferase genetic polymorphisms in adult patients with inflammatory bowel diseases in the Latvian population.

Authors:  Polina Zalizko; Juris Stefanovics; Jelizaveta Sokolovska; Natalia Paramonova; Evija Klavina; Renars Erts; Vita Rovite; Janis Klovins; Aldis Pukitis
Journal:  Therap Adv Gastroenterol       Date:  2020-07-14       Impact factor: 4.409

5.  TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India.

Authors:  Narinder Grover; Prateek Bhatia; Antriksh Kumar; Minu Singh; Deepesh Lad; Harshal S Mandavdhare; Jayanta Samanta; Kaushal K Prasad; Usha Dutta; Vishal Sharma
Journal:  BMC Gastroenterol       Date:  2021-08-23       Impact factor: 3.067

Review 6.  Precision medicine for rheumatologists: lessons from the pharmacogenomics of azathioprine.

Authors:  Laura L Daniel; Alyson L Dickson; Cecilia P Chung
Journal:  Clin Rheumatol       Date:  2020-07-02       Impact factor: 2.980

7.  Nucleoside diphosphate-linked moiety X-type motif 15 R139C genotypes impact 6-thioguanine nucleotide cut-off levels to predict thiopurine-induced leukopenia in Crohn's disease patients.

Authors:  Xia Zhu; Kang Chao; Miao Li; Wen Xie; Hong Zheng; Jin-Xin Zhang; Pin-Jin Hu; Min Huang; Xiang Gao; Xue-Ding Wang
Journal:  World J Gastroenterol       Date:  2019-10-14       Impact factor: 5.742

Review 8.  Can We Predict the Toxicity and Response to Thiopurines in Inflammatory Bowel Diseases?

Authors:  Raphael P Luber; Sailish Honap; Georgina Cunningham; Peter M Irving
Journal:  Front Med (Lausanne)       Date:  2019-11-28

Review 9.  Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era?

Authors:  Carla J Gargallo-Puyuelo; Viviana Laredo; Fernando Gomollón
Journal:  Front Med (Lausanne)       Date:  2021-07-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.